NCT07293325Recruiting
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months. Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks. Changes in "biological (epigenetic) age" will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition. The aim is to determine whether incretin-based therapies can reverse or slow obesity-related accelerated epigenetic aging and to provide new clinical evidence for interventions targeting obesity and aging.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- First submitted
- 24 Nov 2025
- Start date
- 2 Jun 2025
- Primary completion date
- 2 Apr 2027
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Obesity
- NCT number
- NCT07293325
What you commit to
- Study type: Interventional
- Planned participants: 66
- From 2 Jun 2025 to the primary completion date, 2 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of anti-obesity medications or participation in another weight-loss program within the past 3 months.
Other illness
- Presence of secondary obesity (e.g., endocrine disorders such as Cushing's syndrome or hypothyroidism).
- Diagnosed type 1 or type 2 diabetes mellitus requiring hypoglycemic drug therapy.
- History of pancreatitis, severe gastrointestinal disease, or bariatric surgery.
- Severe cardiovascular, hepatic, renal, or psychiatric disease that may affect participation.
- Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Other
- Pregnant or breastfeeding women, or women planning pregnancy during the study period.
- Current participation in any other clinical trial.
Who the study is looking for
- Adults aged 18 to 75 years.
- Diagnosed with simple obesity, defined as BMI ≥ 30 kg/m².
- Have not used any anti-obesity medications (including GLP-1 RAs, tirzepatide, metformin for weight loss, etc.) within the past 3 months.
- Able and willing to comply with study procedures and complete follow-up assessments.
- Provide written informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Affiliated Hospital Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.